December 9, 2016 / 12:06 AM / 8 months ago

BRIEF-Sirtex Medical provides FY ending June 2017 guidance

Dec 9 (Reuters) - Sirtex Medical Ltd :

* On a full year basis, worldwide dose sales growth is anticipated to be in order of 5-11% compared to growth of 16.4% achieved in fy16

* Constant currency EBITDA for full year is anticipated to be in range $65-74 million Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below